Literature DB >> 18957876

Effects of ubiquinone (coenzyme Q10) on myopathy in statin users.

Carel F Schaars1, Anton F H Stalenhoef.   

Abstract

PURPOSE OF REVIEW: Statins are associated with muscle complaints, including myositis. The mechanism through which statin use causes muscle toxicity is unknown. One of the theories is that statin therapy reduces coenzyme Q10 levels in muscle mitochondria, which leads to muscle injury and myopathy. The aim of the present article is to review published data on the association between coenzyme Q10 and statin-associated myopathy. RECENT
FINDINGS: Studies have consistently shown that statins reduce coenzyme Q10 levels in serum and that supplementation of coenzyme Q10 increases these levels. However, the effect of statin therapy on coenzyme Q10 levels in muscle has been conflicting. Recently, two pilot studies on coenzyme Q10 supplementation in statin-induced myopathy and one study on the effect of coenzyme Q10 supplementation on serum muscle enzyme levels were published. These three studies were the first randomized trials with coenzyme Q10 supplementation in hypercholesterolemic patients treated with statins. The results of these trials have been contradictory; whereas one seems to support supplementation with coenzyme Q10, the other two do not.
SUMMARY: This review summarizes the current evidence on coenzyme Q10 supplementation in statin-induced myopathy. We conclude that the present evidence does not support coenzyme Q10 supplementation in statin-induced myopathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18957876     DOI: 10.1097/MOL.0b013e3283168ecd

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  15 in total

1.  Coenzyme Q(10) and statin myalgia: what is the evidence?

Authors:  Emilie Mas; Trevor A Mori
Journal:  Curr Atheroscler Rep       Date:  2010-11       Impact factor: 5.113

2.  Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy.

Authors:  Manish Suneja; Daniel K Fox; Brian D Fink; Judy A Herlein; Christopher M Adams; William I Sivitz
Journal:  Transl Res       Date:  2015-01-28       Impact factor: 7.012

Review 3.  Oxidative stress as a possible mechanism of statin-induced myopathy.

Authors:  Yasin Ahmadi; Amir Ghorbanihaghjo; Mohsen Naghi-Zadeh; Neda Lotfi Yagin
Journal:  Inflammopharmacology       Date:  2018-03-24       Impact factor: 4.473

Review 4.  Update on toxic myopathies.

Authors:  F L Mastaglia; M Needham
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

5.  Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes.

Authors:  Hyo-Bum Kwak; Anna Thalacker-Mercer; Ethan J Anderson; Chien-Te Lin; Daniel A Kane; Nam-Sihk Lee; Ronald N Cortright; Marcas M Bamman; P Darrell Neufer
Journal:  Free Radic Biol Med       Date:  2011-10-25       Impact factor: 7.376

6.  The mitochondrial unfolded protein response activator ATFS-1 protects cells from inhibition of the mevalonate pathway.

Authors:  Manish Rauthan; Parmida Ranji; Nataly Aguilera Pradenas; Christophe Pitot; Marc Pilon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

7.  L-Carnitine, but not coenzyme Q10, enhances the anti-osteoporotic effect of atorvastatin in ovariectomized rats.

Authors:  Hussam A S Murad
Journal:  J Zhejiang Univ Sci B       Date:  2016-01       Impact factor: 3.066

8.  Farnesyltransferase inhibitor improved survival following endotoxin challenge in mice.

Authors:  Shohei Shinozaki; Yoko Inoue; Wen Yang; Makiko Fukaya; Edward A Carter; Yong-Ming Yu; Young Ming-Yu; Alan Fischman; Ronald Tompkins; Masao Kaneki
Journal:  Biochem Biophys Res Commun       Date:  2009-12-23       Impact factor: 3.575

9.  Statins Increase Plasminogen Activator Inhibitor Type 1 Gene Transcription through a Pregnane X Receptor Regulated Element.

Authors:  Frederick M Stanley; Kathryn M Linder; Timothy J Cardozo
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

10.  Resveratrol for protection against statin toxicity in C2C12 and H9c2 cells.

Authors:  Chama Attalah Nee Rezkallah; Angkana Thongkum; Chao Zhu; Qin M Chen
Journal:  J Biochem Mol Toxicol       Date:  2020-03-20       Impact factor: 3.642

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.